BWAY
BrainsWay Ltd. [BWAY] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
BWAY Stock Summary
Top 10 Correlated ETFs
BWAY
Top 10 Correlated Stocks
BWAY
In the News
BWAY Financial details
Company Rating
Buy
Market Cap
85.68M
Income
-4.2M
Revenue
31.79M
Book val./share
2.58
Cash/share
2.85
Dividend
-
Dividend %
-
Employees
134
Optionable
No
Shortable
Yes
Earnings
29 May 2024
P/E
-13.66
Forward P/E
-
PEG
1.94
P/S
3.77
P/B
2.71
P/C
1.68
P/FCF
-30.95
Quick Ratio
5.76
Current Ratio
6.36
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.26
EPS next Y
-
EPS next Q
-
EPS this Y
-70.11%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-23.77%
Revenue last 5Y
6.59%
Revenue Q/Q
8.76%
EPS Q/Q
-155.63%
-
-
-
-
SMA20
-16.67%
SMA50
-16.67%
SMA100
-
Inst Own
23.9%
Inst Trans
1.02%
ROA
-14%
ROE
-19%
ROC
-0.18%
Gross Margin
73%
Oper. Margin
-33%
Profit Margin
-28%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.38-7.615
52W High
-31.56%
52W Low
+379.06%
RSI
34
Rel Volume
0.62
Avg Volume
115.65K
Volume
71.82K
Perf Week
-11.29%
Perf Month
-19.49%
Perf Quarter
49.24%
Perf Half Y
40.49%
-
-
-
-
Beta
0.346
-
-
Volatility
0.16%, 0.38%
Prev Close
-5.14%
Price
4.7906
Change
-6.98%
BWAY Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 2.25 | 1.97 | 1.9 | 1.77 | 1.97 | |
| Net income per share | -1.01 | -0.48 | -0.41 | -0.87 | -0.26 | |
| Operating cash flow per share | -0.71 | -0.13 | 0.06 | -0.63 | 0.08 | |
| Free cash flow per share | -1.03 | -0.35 | -0.09 | -0.51 | -0.07 | |
| Cash per share | 2.14 | 1.53 | 3.68 | 3.11 | 2.85 | |
| Book value per share | 2.36 | 1.75 | 3.68 | 2.95 | 2.58 | |
| Tangible book value per share | 2.36 | 1.75 | 3.68 | 2.95 | 2.95 | |
| Share holders equity per share | 2.36 | 1.75 | 3.68 | 2.95 | 2.58 | |
| Interest debt per share | 0.08 | 0.09 | 0.14 | 0.03 | 0 | |
| Market cap | 99.97M | 84.59M | 119.94M | 38M | 104.6M | |
| Enterprise value | 78.71M | 68.06M | 103.78M | -9.09M | 94.08M | |
| P/E ratio | -9.68 | -15.71 | -18.56 | -2.85 | -24.92 | |
| Price to sales ratio | 4.33 | 3.84 | 4.04 | 1.4 | 3.29 | |
| POCF ratio | -13.8 | -58.91 | 135.68 | -3.89 | 81.47 | |
| PFCF ratio | -9.47 | -21.66 | -88.58 | -4.86 | -92.98 | |
| P/B Ratio | 4.13 | 4.31 | 2.09 | 0.84 | 2.52 | |
| PTB ratio | 4.13 | 4.31 | 2.09 | 0.84 | 2.52 | |
| EV to sales | 3.41 | 3.09 | 3.5 | -0.33 | 2.96 | |
| Enterprise value over EBITDA | -11.96 | -14.09 | -31.32 | 0.82 | -25.98 | |
| EV to operating cash flow | -10.87 | -47.39 | 117.39 | 0.93 | 73.27 | |
| EV to free cash flow | -7.46 | -17.42 | -76.64 | 1.16 | -83.63 | |
| Earnings yield | -0.1 | -0.06 | -0.05 | -0.35 | -0.04 | |
| Free cash flow yield | -0.11 | -0.05 | -0.01 | -0.21 | -0.01 | |
| Debt to equity | 0.02 | 0.03 | 0.01 | 0.01 | 0 | |
| Debt to assets | 0.01 | 0.02 | 0.01 | 0.01 | 0 | |
| Net debt to EBITDA | 3.23 | 3.42 | 4.88 | 4.22 | 2.9 | |
| Current ratio | 4.29 | 3.57 | 7.22 | 7.14 | 5.68 | |
| Interest coverage | -21.3 | -15.14 | -3.52 | -275.72 | 0 | |
| Income quality | 0.7 | 0.27 | -0.14 | 0.73 | -0.31 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.19 | 0.21 | 0.2 | 0.25 | 0 | |
| Research and developement to revenue | 0.34 | 0.26 | 0.22 | 0.28 | 0.21 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.46 | 1.72 | -2.53 | -0.2 | -1.88 | |
| Capex to revenue | -0.14 | -0.11 | -0.08 | 0.07 | -0.08 | |
| Capex to depreciation | -1.18 | -0.92 | -1.33 | 1.26 | -1.8 | |
| Stock based compensation to revenue | 0.05 | 0.04 | 0.06 | 0.05 | 0 | |
| Graham number | 7.32 | 4.35 | 5.86 | 7.59 | 3.88 | |
| ROIC | -0.35 | -0.24 | -0.09 | -0.28 | -0.13 | |
| Return on tangible assets | -0.27 | -0.16 | -0.09 | -0.21 | -0.07 | |
| Graham Net | 1.17 | 0.75 | 2.81 | 2.23 | 2.27 | |
| Working capital | 22.11M | 17.5M | 56.38M | 49.95M | 45.7M | |
| Tangible asset value | 24.22M | 19.63M | 57.32M | 45.4M | 47.66M | |
| Net current asset value | 14.31M | 9.92M | 47.04M | 39.01M | 40.15M | |
| Invested capital | 0.02 | 0.03 | 0.01 | 0.01 | 0 | |
| Average receivables | 4.97M | 6.54M | 6.72M | 5.59M | 5.17M | |
| Average payables | 1.78M | 2.94M | 2.83M | 1.11M | 937K | |
| Average inventory | 198.5K | 374K | 321K | 2.02M | 3.78M | |
| Days sales outstanding | 94.11 | 117.76 | 77.93 | 65.06 | 63.07 | |
| Days payables outstanding | 93.94 | 328.34 | 61.01 | 57.14 | 33.3 | |
| Days of inventory on hand | 21.78 | 31.9 | 11.06 | 196.45 | 163.3 | |
| Receivables turnover | 3.88 | 3.1 | 4.68 | 5.61 | 5.79 | |
| Payables turnover | 3.89 | 1.11 | 5.98 | 6.39 | 10.96 | |
| Inventory turnover | 16.76 | 11.44 | 33 | 1.86 | 2.24 | |
| ROE | -0.43 | -0.27 | -0.11 | -0.29 | -0.1 | |
| Capex per share | -0.32 | -0.22 | -0.14 | 0.13 | -0.15 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.37 | 0.41 | 0.48 | 0.51 | 0.56 | |
| Net income per share | -0.24 | -0.15 | -0.1 | -0.01 | 0.01 | |
| Operating cash flow per share | -0.14 | -0.22 | 0.06 | 0.08 | 0.15 | |
| Free cash flow per share | -0.02 | -0.22 | -0.03 | 0.05 | 0.13 | |
| Cash per share | 2.97 | 2.75 | 2.69 | 2.74 | 2.85 | |
| Book value per share | 2.82 | 2.66 | 2.56 | 2.55 | 2.58 | |
| Tangible book value per share | 2.82 | 2.66 | 2.56 | 2.55 | 2.95 | |
| Share holders equity per share | 2.82 | 2.66 | 2.56 | 2.55 | 2.58 | |
| Interest debt per share | -0.01 | -0.09 | 0.26 | 0.29 | 0.01 | |
| Market cap | 39.8M | 28.33M | 36.8M | 65.21M | 104.6M | |
| Enterprise value | -7.3M | -10.96M | -1.51M | 26.24M | 94.08M | |
| P/E ratio | -2.57 | -2.91 | -5.53 | -70.89 | 205.91 | |
| Price to sales ratio | 6.6 | 4.28 | 4.7 | 7.86 | 11.59 | |
| POCF ratio | -17.75 | -8 | 36.99 | 48.09 | 42.28 | |
| PFCF ratio | -130.06 | -8 | -73.32 | 77.45 | 51.83 | |
| P/B Ratio | 0.88 | 0.66 | 0.89 | 1.58 | 2.52 | |
| PTB ratio | 0.88 | 0.66 | 0.89 | 1.58 | 2.52 | |
| EV to sales | -1.21 | -1.65 | -0.19 | 3.16 | 10.42 | |
| Enterprise value over EBITDA | 1.83 | 3.28 | 1.5 | 131.88 | 179.89 | |
| EV to operating cash flow | 3.25 | 3.09 | -1.51 | 19.35 | 38.03 | |
| EV to free cash flow | 23.84 | 3.09 | 3 | 31.17 | 46.62 | |
| Earnings yield | -0.1 | -0.09 | -0.05 | 0 | 0 | |
| Free cash flow yield | -0.01 | -0.13 | -0.01 | 0.01 | 0.02 | |
| Debt to equity | 0.01 | 0 | 0.1 | 0.11 | 0 | |
| Debt to assets | 0.01 | 0 | 0.07 | 0.08 | 0 | |
| Net debt to EBITDA | 11.83 | 11.76 | 38.2 | -195.83 | -20.11 | |
| Current ratio | 7.14 | 6.13 | 6.98 | 6.36 | 5.68 | |
| Interest coverage | 6.12 | 2.61 | -9.95 | -3.5 | 0.83 | |
| Income quality | 0.58 | 1.46 | -0.6 | -5.9 | 19.48 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.29 | 0.27 | 0.15 | 0.14 | 0 | |
| Research and developement to revenue | 0.36 | 0.27 | 0.24 | 0.19 | 0.16 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | -0.86 | 0 | -1.5 | -0.38 | -0.18 | |
| Capex to revenue | 0.32 | 0 | -0.19 | -0.06 | -0.05 | |
| Capex to depreciation | 5.64 | -0.01 | -4.4 | -1.55 | -1.35 | |
| Stock based compensation to revenue | 0.06 | -0.01 | 0.01 | 0.01 | 0 | |
| Graham number | 3.9 | 3 | 2.44 | 0.9 | 0.68 | |
| ROIC | -0.09 | -0.08 | -0.03 | 0 | -0.02 | |
| Return on tangible assets | -0.06 | -0.04 | -0.03 | 0 | 0 | |
| Graham Net | 2.13 | 1.96 | 1.84 | 1.85 | 2.27 | |
| Working capital | 49.95M | 46.98M | 44.61M | 44.28M | 45.7M | |
| Tangible asset value | 45.4M | 42.92M | 41.36M | 41.22M | 47.66M | |
| Net current asset value | 39.01M | 37.11M | 34.18M | 33.99M | 40.15M | |
| Invested capital | 0.01 | 0 | 0.1 | 0.11 | 0 | |
| Average receivables | 5.22M | 5.1M | 4.38M | 3.42M | 4.46M | |
| Average payables | 1.2M | 850K | 561.5K | 516K | 625.5K | |
| Average inventory | 3.54M | 4.29M | 4.02M | 3.4M | 3.61M | |
| Days sales outstanding | 72.26 | 72.68 | 39.27 | 37.05 | 54.74 | |
| Days payables outstanding | 58.09 | 29.33 | 23.16 | 20.82 | 29.79 | |
| Days of inventory on hand | 199.73 | 237.86 | 141.81 | 147.99 | 146.08 | |
| Receivables turnover | 1.25 | 1.24 | 2.29 | 2.43 | 1.64 | |
| Payables turnover | 1.55 | 3.07 | 3.89 | 4.32 | 3.02 | |
| Inventory turnover | 0.45 | 0.38 | 0.63 | 0.61 | 0.62 | |
| ROE | -0.09 | -0.06 | -0.04 | -0.01 | 0 | |
| Capex per share | 0.12 | 0 | -0.09 | -0.03 | -0.03 |
BWAY Frequently Asked Questions
What is BrainsWay Ltd. stock symbol ?
BrainsWay Ltd. is a IL stock and trading under the symbol BWAY
What is BrainsWay Ltd. stock quote today ?
BrainsWay Ltd. stock price is $4.7906 today.
Is BrainsWay Ltd. stock public?
Yes, BrainsWay Ltd. is a publicly traded company.
Company Profile
- Volume Average 115.65K
- Market Capitalization 85.68M
- Employee 134
- CEO Mr. Hadar Levy
- Headquarters Jerusalem,IL
- IPO Date 2019-04-17
-
Website
https://www.brainsway.com 
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
